Yang Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yang Yang has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Lingyu Jiang
School of Pharmacology, Binzhou Medical University, Yantai, Shandong 264003, P.R. China
1 shared publicationShuyan Liu
School of Pharmacology, Binzhou Medical University, Yantai, Shandong 264003, P.R. China
1 shared publicationTingzhi Deng
School of Pharmacology, Binzhou Medical University, Yantai, Shandong 264003, P.R. China
1 shared publication- Yin Zhang
Shandong Medical and Pharmaceutical University Hospital, Shandong Pharmaceutical University, Binzhou, China
1 shared publication
Latest Publications
- Open Access
- 7 June 2022
- Published by Spandidos Publications in Oncology Letters
- Vol. 24 (2) , 1-11
Analysis of the expression, function and signaling of glycogen phosphorylase isoforms in hepatocellular carcinoma
Glycogen phosphorylase (GP) is an essential enzyme for glycolysis via the glycogen degradation pathway. It consists of three isoforms: PYGB (brain form), PYGL (liver form) and PYGM (muscle form). Although the abnormal expression of GP is associated with a variety of tumors, its relationship with hepatocellular carcinoma (HCC) and whether it can be used as a prognostic marker of HCC remains unclear. In the present study, the expression levels of PYGB, PYGL and PYGM were analyzed. It was found that the expression levels of PYGB in tumor tissues were higher than those in normal tissues, particularly in HCC. The high expression of PYGB (hazard ratios=1.801; 95% confidence interval: 1.266‑2.562) could predict the poor prognosis of HCC patients but not PYGL and PYGM. Inhibition of PYGB with GP inhibitor CP91149 significantly suppressed the HCC cell proliferation in the HCC cell model. In addition, combination treatment with sorafenib, a standard treatment for HCC, showed a great inhibition on tumor growth and angiogenesis. These findings suggested that PYGB may be used as a therapeutic and prognostic indicator for HCC.
- 7 June 2022
- Published by Spandidos Publications in Oncology Letters
- Vol. 24 (2) , 1-11
Open AccessAnalysis of the expression, function and signaling of glycogen phosphorylase isoforms in hepatocellular carcinoma
Glycogen phosphorylase (GP) is an essential enzyme for glycolysis via the glycogen degradation pathway. It consists of three isoforms: PYGB (brain form), PYGL (liver form) and PYGM (muscle form). Although the abnormal expression of GP is associated with a variety of tumors, its relationship with hepatocellular carcinoma (HCC) and whether it can be used as a prognostic marker of HCC remains unclear. In the present study, the expression levels of PYGB, PYGL and PYGM were analyzed. It was found that the expression levels of PYGB in tumor tissues were higher than those in normal tissues, particularly in HCC. The high expression of PYGB (hazard ratios=1.801; 95% confidence interval: 1.266‑2.562) could predict the poor prognosis of HCC patients but not PYGL and PYGM. Inhibition of PYGB with GP inhibitor CP91149 significantly suppressed the HCC cell proliferation in the HCC cell model. In addition, combination treatment with sorafenib, a standard treatment for HCC, showed a great inhibition on tumor growth and angiogenesis. These findings suggested that PYGB may be used as a therapeutic and prognostic indicator for HCC.